Virtual ISPOR

What Can US Learn About Biosimilars From Europe?

May 24th 2019

Article

Europe has several lessons for the US biosimilar market, according to a pharmaceutical executive who spoke during ISPOR 2019.

Fresenius Kabi's Adalimumab Biosimilar Produces Comparable QOL Improvements to Humira

May 22nd 2019

Article

Treatment with the biosimilar, the investigators concluded, resulted in comparable, maintained quality of life improvements that were not impacted by a switch from the reference product.

Biosimilar Monotherapy Sequence for RA Can Be Considered Cost-Effective, Study Finds

May 21st 2019

Article

Rheumatoid arthritis (RA) has a considerable economic burden, and costly biologics, are often restricted to cases in which patients fail to respond adequately to methotrexate or other conventional disease-modifying antirheumatic drugs, which may be difficult for some patients to tolerate.

Researchers Predict Substantial Savings for Europe on the Strength of Biosimilar Adalimumab

May 21st 2019

Article

During the ISPOR 2019 annual meeting, teams of investigators presented data estimating just how much healthcare systems could save by adopting biosimilar adalimumab for all indications of its reference in adult patients. The results highlighted both the scale of potential savings and the variability among European nations.

Health Plan Restrictions Likely to Have an Impact on Biosimilars, Orphan Drugs

May 20th 2019

Article

Despite their benefits to patients, innovative treatments, including biologics, come at a high cost to the healthcare system, and those in a position to make coverage decisions for these products must grapple with these therapies’ affordability. During the ISPOR 2019 meeting, researchers presented findings on how health plan restrictions could limit orphan drug coverage—and encourage biosimilar use—as a means to manage their budgets.

Biologics in IBD Linked With Lower Surgery Costs, Corticosteroid Use, and Opioid Use

May 19th 2019

Article

Research presented at this week’s ISPOR 2019 meeting sheds important light on the impact of biologics on the use of other healthcare resources.

Researchers Present Findings on Patient Preferences, Outcomes With G-CSFs

May 18th 2019

Article

During this week’s meeting of the International Society for Pharmacoeconomic and Outcomes Research, held from May 18 to 22 in New Orleans, Louisiana, researchers presented findings on both the patient attitudes toward granulocyte colony-stimulating factor (G-CSF) therapies and their effectiveness in the prophylaxis of febrile neutropenia.

7 Biosimilars Takeaways from ISPOR 2018

May 27th 2018

Article

At the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland, researchers and speakers highlighted emerging trends in biosimilars. Here are 7 key takeaways from the conference.

Time to Market Entry and Shallow Discounts Delay Biosimilar Savings, but Interchangeability Could Help

May 24th 2018

Article

As the United States lags behind Europe and other highly regulated areas in terms of biosimilar approval and uptake, research presented during the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting in Baltimore, Maryland, points to slow market entry and small price discounts of approved biosimilar products as key factors that are holding up cost savings in the US market.

BBCIC Seeks to Provide Stakeholders With Real-World Data on Biosimilars

May 24th 2018

Article

At the International Society for Pharmacoeconomics and Outcomes Research 23rd Annual International Meeting, in Baltimore, Maryland, members of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) discussed the ways in which their organization, a not-for-profit entity that conducts postmarketing observational research to monitor biosimilars and novel biologics for efficacy and safety, is working to provide real-world evidence on these products to stakeholders.